Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21518244 | 0.93 | LMNA (0.49) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL27210212 | 0.85 | CYP2D6 (0.44) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL29546194 | 0.85 | CYP2D6 (0.44) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL10687435 | 0.84 | LMNA (0.53) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL6324521 | 0.84 | LMNA (0.53) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL6324514 | 0.84 | LMNA (0.53) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL18241062 | 0.84 | CYP2D6 (0.47) | LMNAKMT2ACYP3A4MAPTCYP2C9 | |
| SCHEMBL18241081 | 0.84 | CYP2D6 (0.47) | LMNAKMT2ACYP3A4MAPTCYP2C9 | |
| SCHEMBL21332149 | 0.84 | CYP3A4 (0.46) | LMNAKMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL18102364 | 0.83 | LMNA (0.52) | LMNAKMT2AALDH1A1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2022-01-27 | — | — | US | disclosed |
| EP-3558323-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | Etablissement Français du Sang (FR) | 2019-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | TLR4, TLR3, TLR2 | LMNA 2057/4885KMT2A 574/4885ALDH1A1 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.